Spyre Therapeutics, Inc. (SYRE)
(Delayed Data from NSDQ)
$26.19 USD
-0.73 (-2.71%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $26.15 -0.04 (-0.15%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SYRE 26.19 -0.73(-2.71%)
Will SYRE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SYRE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SYRE
Here's What Could Help Spyre Therapeutics (SYRE) Maintain Its Recent Price Strength
Here's Why Spyre Therapeutics (SYRE) Could be Great Choice for a Bottom Fisher
SYRE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for SYRE
Commit To Buy Spyre Therapeutics At $20, Earn 15.7% Annualized Using Options
Spyre Therapeutics management to meet virtually with BTIG
Spyre Therapeutics management to meet virtually with BTIG
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
Spyre Therapeutics management to meet virtually with BTIG